Page 133 - 《中国药房》2022年16期

[ 9 ] BARNES H，YEOH H L，FOTHERGILL T，et al. Prosta- for the treatment of pulmonary arterial hypertension[J]. N
cyclin for pulmonary arterial hypertension[J]. Cochrane Engl J Med，2015，373（26）：2522-2533.
Database Syst Rev，2019，5（5）：CD012785. [21] GAINE S，SITBON O，CHANNICK R N，et al. Relation-
[10] KUWANO K，HASHINO A，ASAKI T，et al. 2-{4-[（5， ship between time from diagnosis and morbidity/mortality
6-diphenylpyrazin-2-yl）（isopropyl） amino]butoxy}-N- in pulmonary arterial hypertension：results from the phase
（methylsulfonyl）acetamide（NS-304），an orally available Ⅲ GRIPHON study[J]. Chest，2021，160（1）：277-286.
and long-acting prostacyclin receptor agonist prodrug[J]. J [22] MCLAUGHLIN V，CHIN K，FARBER H，et al. Clinical
Pharmacol Exp Ther，2007，322（3）：1181-1188. characteristics of patients with pulmonary arterial hyper-
[11] KUWANO K，HASHINO A，NODA K，et al. A long- tension and treatment patterns：a real-world analysis from
acting and highly selective prostacyclin receptor agonist sphere（selexipag：the users drug registry）[J]. Chest，2021，
prodrug，2-{4-[（5，6-diphenylpyrazin-2-yl）（isopropyl） 160（4）：A2292-A2295.
amino]butoxy}-N-（methylsulfonyl）acetamide（NS-304）， [23] COGHLAN G J，GAINE S，CHANNICK R N，et al. Treat-
ameliorates rat pulmonary hypertension with unique rela- ment effect of selexipag on time to disease progression
xant responses of its active form，{4-[（5，6-diphenylpyrazin- when initiated early in pulmonary arterial hypertension
2-yl）（isopropyl）amino]butoxy} acetic acid（MRE-269）， （PAH）patients：GRIPHON and TRITON pooled analy-
sis[J]. Eur Heart J，2021，42（supplement_1）：ehab724.1964.
on rat pulmonary artery[J]. J Pharmacol Exp Ther，2008，
[24] KIM N H，HEMNES A R，CHAKINALA M M，et al. Pa-
326（3）：691-699.
tient and disease characteristics of the first 500 patients
[12] KAUFMANN P，HURST N，ASTRUC B，et al. Absolute
with pulmonary arterial hypertension treated with selexi-
oral bioavailability of selexipag，a novel oral prostacyclin
pag in real-world settings from SPHERE[J]. J Heart Lung
IP receptor agonist[J]. Eur J Clin Pharmacol，2017，73（2）：
Transplant，2021，40（4）：279-288.
151-156.
[25] HOWARD L，ROSENKRANZ S，FRANTZ R，et al. As-
[13] 刘嫄，胡欣，史爱欣.肺动脉高压新型靶向治疗药物的临
sessing daily life physical activity by actigraphy in pulmo-
床研究进展[J].中国药房，2017，28（32）：4589-4592.
nary arterial hypertension：insights from the randomized
[14] 郭宗儒，ASAKI T，KUWANO K，等.治疗肺动脉高压药
controlled study with selexipag（TRACE）[J]. Chest，2020，
物赛乐西帕[J].药学学报，2018，53（12）：2129-2134.
158（4 supplement）：A2449-A2451.
[15] ASAKI T，KUWANO K，MORRISON K，et al. Selexipag：
[26] BURGER C D，DUBROCK H M，CARTIN-CEBA R，et al.
an oral and selective IP prostacyclin receptor agonist for
Topic-based，recent literature review on pulmonary hyper-
the treatment of pulmonary arterial hypertension[J]. J Med
tension[J]. Mayo Clin Proc，2021，96（12）：3109-3121.
Chem，2015，58（18）：7128-7137.
[27] 刘丽辉，陈光福，蔡茵莎，等.增用司来帕格片对肺动脉高
[16] SIMONNEAU G，TORBICKI A，HOEPER M M，et al.
压患儿的疗效及安全性分析[J].临床肺科杂志，2020，25
Selexipag：an oral，selective prostacyclin receptor agonist
（2）：232-235.
for the treatment of pulmonary arterial hypertension[J].
[28] HANSMANN G，MEINEL K，BUKOVA M，et al. Selexi-
Eur Respir J，2012，40（4）：874-880. pag for the treatment of children with pulmonary arterial
[17] CHIN K M，SITBON O，DOELBERG M，et al. Three- hypertension：first multicenter experience in drug safety
versus two-drug therapy for patients with newly diag- and efficacy[J]. J Heart Lung Transplant，2020，39（7）：
nosed pulmonary arterial hypertension[J]. J Am Coll Car- 695-706.
diol，2021，78（14）：1393-1403. [29] BRAVO-VALENZUELA N J M，NAVARRO F，SILVA S
[18] CHIN K M，SITBON O，DOELBERG M，et al. Efficacy P. Use of selexipag in a teenage patient with pulmonary
and safety of initial triple oral versus initial double oral arterial hypertension[J]. Ann Pediatr Cardiol，2021，14
combination therapy in patients with newly diagnosed pul- （1）：75-78.
monary arterial hypertension（PAH）：results of the ran- [30] GEERDINK L M，BERTRAM H，HANSMANN G.
domized controlled TRITON study[J]. Am J Resp Crit First-in-child use of the oral selective prostacyclin IP
Care，2020，201：A2928. receptor agonist selexipag in pulmonary arterial hyperten-
[19] MOMOI M，HIRAIDE T，SHINYA Y，et al. Triple oral sion[J]. Pulm Circ，2017，7（2）：551-554.
combination therapy with macitentan，riociguat，and sele- [31] GALLOTTI R，DROGALIS-KIM D E，SATOU G，et al.
xipag for pulmonary arterial hypertension[J]. Ther Adv Single-center experience using selexipag in a pediatric
Respir Dis，2021，15：1753466621995048. population[J]. Pediatr Cardiol，2017，38（7）：1405-1409.
[20] SITBON O，CHANNICK R，CHIN K M，et al. Selexipag （下转第2048页）

中国药房 2022年第33卷第16期 China Pharmacy 2022 Vol. 33 No. 16 ·2043 ·